TECELRA Receives Full FDA Approval, Expands Access to Adolescents with Synovial Sarcoma
US WorldMeds® announced that the U.S. Food and Drug Administration has granted full approval to TECELRA® (afamitresgene autoleucel), with an expanded indication that now includes eligible patients as young as 12 years old. The therapy, which received its original accelerated approval in August 2024, remains…
11 Leading Oncologists and Researchers Unite to Accelerate Progress for Synovial Sarcoma Patients PHILADELPHIA [June 22, 2026] The Synovial Sarcoma Foundation (SSF) today announced the formation of its Medical Advisory Board, bringing together 11 internationally recognized clinicians and researchers to serve as the central coordinating…
Breaking Down Synovial Sarcoma’s Defenses: A study on Immune Evasion and Targeted Treatment
A landmark study from Jerby-Arnon, Neftel, Shore, and colleagues at the Broad Institute of Harvard and MIT, Massachusetts General Hospital, Dana-Farber Cancer Institute, and the University of Lausanne used single-cell RNA sequencing to profile 16,872 individual cells from 12 human synovial sarcoma tumors – one…
Post-Surgical Complication in Synovial Sarcoma: Rare Case Highlights Pleural Aspergillosis Risk
A recent case report describes a rare but serious complication in a patient with metastatic synovial sarcoma of the lung—highlighting…
Rare Tumor Case Highlights Importance of Accurate Diagnosis in Sarcoma Care
A recent case report describes an extremely rare solitary fibrous tumor (SFT) occurring in the maxilla (upper jaw), highlighting the…
Rare Disease Drug Development and Synovial Sarcoma: Why Funding Still Falls Short
A recent BioSpace article highlights a critical challenge in rare disease drug development: many promising therapies are not limited by…
Synovial Sarcoma in Children: A Rare Case Affecting the Lung
Most synovial sarcoma tumors develop in the soft tissues near the joints of the arms or legs in adolescents and…
Synovial Sarcoma Research Pipeline Grows as 15+ Companies Develop New Therapies
Recent industry analyses show that the synovial sarcoma clinical trial pipeline is expanding, with more than 15 companies developing over…
Targeted Therapy Shows Promise in Rare BRAF-Mutated Synovial Sarcoma
Synovial sarcoma is a rare soft tissue sarcoma most commonly treated with surgery, chemotherapy, radiation therapy, and targeted drugs such…
Synovial Sarcoma Treatment Market Growth Reflects Expanding Research
Recent industry analyses suggest the synovial sarcoma treatment market is expected to grow steadily, with projections estimating a compound annual…
A Turning Point for Rare Cancers
What the UK’s Rare Cancers Bill Means for the Synovial Sarcoma Community For decades, patients diagnosed with rare cancers have…
Afamitresgene Autoleucel (Afami-cel): T-Cell Therapy Shows Promise in Synovial Sarcoma
Synovial sarcoma is a rare and often aggressive cancer that can become difficult to treat once it spreads. Traditional chemotherapy…
